273 related articles for article (PubMed ID: 27665129)
21. Cocrystal dissociation in the presence of water: a general approach for identifying stable cocrystal forms.
Eddleston MD; Madusanka N; Jones W
J Pharm Sci; 2014 Sep; 103(9):2865-2870. PubMed ID: 24824298
[TBL] [Abstract][Full Text] [Related]
22. A novel intravenous vehicle for preclinical cardiovascular screening of small molecule drug candidates in rat.
Banfor PN; Gintant GA; Lipari JM; Zocharski PD
J Pharmacol Toxicol Methods; 2016; 82():62-67. PubMed ID: 27432021
[TBL] [Abstract][Full Text] [Related]
23. Pharmaceutical cocrystals: walking the talk.
Bolla G; Nangia A
Chem Commun (Camb); 2016 Jun; 52(54):8342-60. PubMed ID: 27278109
[TBL] [Abstract][Full Text] [Related]
24. Crystal engineering to improve physicochemical properties of mefloquine hydrochloride.
Yadav AV; Dabke AP; Shete AS
Drug Dev Ind Pharm; 2010 Sep; 36(9):1036-45. PubMed ID: 20334542
[TBL] [Abstract][Full Text] [Related]
25. Anticancer efficacy, tissue distribution and blood pharmacokinetics of surface modified nanocarrier containing melphalan.
Rajpoot P; Bali V; Pathak K
Int J Pharm; 2012 Apr; 426(1-2):219-230. PubMed ID: 22301424
[TBL] [Abstract][Full Text] [Related]
26. A novel solubilization technique for poorly soluble drugs through the integration of nanocrystal and cocrystal technologies.
Karashima M; Kimoto K; Yamamoto K; Kojima T; Ikeda Y
Eur J Pharm Biopharm; 2016 Oct; 107():142-50. PubMed ID: 27393561
[TBL] [Abstract][Full Text] [Related]
27. Thermodynamics of Highly Supersaturated Aqueous Solutions of Poorly Water-Soluble Drugs-Impact of a Second Drug on the Solution Phase Behavior and Implications for Combination Products.
Trasi NS; Taylor LS
J Pharm Sci; 2015 Aug; 104(8):2583-93. PubMed ID: 26059413
[TBL] [Abstract][Full Text] [Related]
28. Optimising the in vitro and in vivo performance of oral cocrystal formulations via spray coating.
Serrano DR; Walsh D; O'Connell P; Mugheirbi NA; Worku ZA; Bolas-Fernandez F; Galiana C; Dea-Ayuela MA; Healy AM
Eur J Pharm Biopharm; 2018 Mar; 124():13-27. PubMed ID: 29196273
[TBL] [Abstract][Full Text] [Related]
29. Salt Disproportionation in the Solid State: Role of Solubility and Counterion Volatility.
Thakral NK; Behme RJ; Aburub A; Peterson JA; Woods TA; Diseroad BA; Suryanarayanan R; Stephenson GA
Mol Pharm; 2016 Dec; 13(12):4141-4151. PubMed ID: 27766882
[TBL] [Abstract][Full Text] [Related]
30. Formulation of a danazol cocrystal with controlled supersaturation plays an essential role in improving bioavailability.
Childs SL; Kandi P; Lingireddy SR
Mol Pharm; 2013 Aug; 10(8):3112-27. PubMed ID: 23822591
[TBL] [Abstract][Full Text] [Related]
31. Polymorphism in sulfadimidine/4-aminosalicylic acid cocrystals: solid-state characterization and physicochemical properties.
Grossjohann C; Serrano DR; Paluch KJ; O'Connell P; Vella-Zarb L; Manesiotis P; Mccabe T; Tajber L; Corrigan OI; Healy AM
J Pharm Sci; 2015 Apr; 104(4):1385-98. PubMed ID: 25605031
[TBL] [Abstract][Full Text] [Related]
32. Cocrystallization for successful drug delivery.
Sun CC
Expert Opin Drug Deliv; 2013 Feb; 10(2):201-13. PubMed ID: 23256822
[TBL] [Abstract][Full Text] [Related]
33. Strategies at the interface of drug discovery and development: early optimization of the solid state phase and preclinical toxicology formulation for potential drug candidates.
Palucki M; Higgins JD; Kwong E; Templeton AC
J Med Chem; 2010 Aug; 53(16):5897-905. PubMed ID: 20527889
[No Abstract] [Full Text] [Related]
34. Formulation design for poorly water-soluble drugs based on biopharmaceutics classification system: basic approaches and practical applications.
Kawabata Y; Wada K; Nakatani M; Yamada S; Onoue S
Int J Pharm; 2011 Nov; 420(1):1-10. PubMed ID: 21884771
[TBL] [Abstract][Full Text] [Related]
35. Biopharmaceutical classification of poorly soluble drugs with respect to "enabling formulations".
Buckley ST; Frank KJ; Fricker G; Brandl M
Eur J Pharm Sci; 2013 Sep; 50(1):8-16. PubMed ID: 23583787
[TBL] [Abstract][Full Text] [Related]
36. Pharmaceutical Cocrystals as an Opportunity to Modify Drug Properties: From the Idea to Application: A Review.
Sokal A; Pindelska E
Curr Pharm Des; 2018; 24(13):1357-1365. PubMed ID: 29278209
[TBL] [Abstract][Full Text] [Related]
37. Challenges in Translational Development of Pharmaceutical Cocrystals.
Kale DP; Zode SS; Bansal AK
J Pharm Sci; 2017 Feb; 106(2):457-470. PubMed ID: 27914793
[TBL] [Abstract][Full Text] [Related]
38. Use of surfactants as plasticizers in preparing solid dispersions of poorly soluble API: stability testing of selected solid dispersions.
Ghebremeskel AN; Vemavarapu C; Lodaya M
Pharm Res; 2006 Aug; 23(8):1928-36. PubMed ID: 16871443
[TBL] [Abstract][Full Text] [Related]
39. Artemisinin Cocrystals for Bioavailability Enhancement. Part 1: Formulation Design and Role of the Polymeric Excipient.
Kaur M; Yardley V; Wang K; Masania J; Botana A; Arroo RRJ; Li M
Mol Pharm; 2021 Dec; 18(12):4256-4271. PubMed ID: 34723557
[TBL] [Abstract][Full Text] [Related]
40. Co amorphous systems: A product development perspective.
Chavan RB; Thipparaboina R; Kumar D; Shastri NR
Int J Pharm; 2016 Dec; 515(1-2):403-415. PubMed ID: 27771485
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
